

Review Article

Role of Different *Pf*crt and *Pf*mdr-1 Mutations in Conferring Resistance to Antimalaria Drugs in *Plasmodium falciparum*

Zaid O. Ibraheem,¹ R. Abd Majid,² S. Mohd. Noor,³ H. Mohd. Sedik,⁴ and R. Basir¹

¹ Pharmacology Unit, Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia

² Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia

³ Department of Hematology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia

⁴ School of Bioscience and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia (UKM), 43600 Bangi, Selangor, Malaysia

Correspondence should be addressed to Zaid O. Ibraheem; zaid.2002.2005@gmail.com and R. Basir; rusliza1909@gmail.com

Received 29 June 2014; Accepted 30 August 2014; Published 11 November 2014

Academic Editor: Polrat Wilairatana

Copyright © 2014 Zaid O. Ibraheem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Emergence of drugs resistant strains of *Plasmodium falciparum* has augmented the scourge of malaria in endemic areas. Antimalaria drugs act on different intracellular targets. The majority of them interfere with digestive vacuoles (DVs) while others affect other organelles, namely, apicoplast and mitochondria. Prevention of drug accumulation or access into the target site is one of the mechanisms that plasmodium adopts to develop resistance. Plasmodia are endowed with series of transporters that shuffle drugs away from the target site, namely, *pfmdr* (*Plasmodium falciparum* multidrug resistance transporter) and *pfcr*t (*Plasmodium falciparum* chloroquine resistance transporter) which exist in DV membrane and are considered as putative markers of CQ resistance. They are homologues to human P-glycoproteins (P-gp or multidrug resistance system) and members of drug metabolite transporter (DMT) family, respectively. The former mediates drifting of xenobiotics towards the DV while the latter chucks them outside. Resistance to drugs whose target site of action is intravacuolar develops when the transporters expel them outside the DVs and vice versa for those whose target is extravacuolar. In this review, we are going to summarize the possible *pfcr*t and *pfmdr* mutation and their role in changing plasmodium sensitivity to different anti-Plasmodium drugs.

1. Resistance to Antimalaria Drugs

Emergence of resistant strains of *Plasmodium falciparum* to the well-known conventional antimalarials has worsened the calamity of malaria scourge. Resistance to chloroquine (CQ) is the most catastrophic factor as it is still the cheapest and safest among all other antimalaria drugs [1, 2]. It was originated in 6 different foci in the world distributed among Africa, South-east Asia, and Latin America [3].

Development of drugs resistance relies entirely on the array of biological and atmospheric factors and the drug

pressure that each strain had experienced during its evolution [4]. For instance, it took decades to develop resistant strains to CQ while resistance to the electron transport inhibitor, atovaquone, may emerge in tandem with its clinical use [5, 6]. The former requires several mutations in the transporter protein [7] whilst only one point mutation is sufficient to confer the latter [8, 9].

Fixed dose combination strategy was adopted by WHO to overwhelm spread of resistance [1]. For instance, prevalence of lumefantrine (LM) resistance is very low due to its use as a part of fixed dose combination therapy along with artemisinin (ART) [10, 11].

2. Intracellular Distribution of Anti-Plasmodium Drugs and Role of Transporter Proteins

Access of antimalaria drugs into their target is a prerequisite for their action. They have different intracellular targets, such as digestive vacuole (DV), cytosol, mitochondria, apicoplast, and parasite membrane [12, 13]. Their intracellular distribution relies on their solubility, potential to permeate cell membranes, and binding affinity to transporters that regulate drugs trafficking through intracellular compartments [14, 15].

Normally, eukaryotic cells evade xenobiotics toxicity through trafficking them into the DVs or lysosomes for further procession or expel them extracellularly [15]. In plasmodium, two types of transporters mediate xenobiotics trafficking to the DV [16]: P-glycoprotein related transporters (which include *pfmdr-1* (*Plasmodium falciparum* multidrug resistance-1), *pfmdr-2* and *pfmrp* (*Plasmodium falciparum* multidrug resistance associated protein)) and drug metabolite transporter (DMT) system that is represented by *pfcr1* (*Plasmodium falciparum* chloroquine resistance transporter). Drugs are trafficked from the cytosol to the intravacuolar compartment by the former and in the opposite direction by the latter [7, 16, 17]. Their function is inconsistent in all the strains as it depends on the drug selection pressure and type of the mutation possessed by the transporter [8, 18, 19].

Different mutations were observed in different strains of *Plasmodium falciparum* [18]. The mutant transporters increase efficacy of drugs as long as they are shuffled into their target site. In other words, if the drug target is intracytosolic, its potency increases when the transporters prevent its accumulation up in the intravacuolar compartment [20–22].

In this review, we are going to summarize the potential of different *pfcr1* and P-glycoprotein transporters on the intracellular distribution of the antimalaria drugs.

3. Digestive Vacuole Membrane Transporters: (i) P-Glycoprotein Transporters and (ii) Drug Metabolite System Transporters

3.1. P-Glycoprotein Transporters. ABC transporters (ATP dependent cassette transporters) or P-glycoprotein (P-gh) is a group of energy mediated carriers which pump xenobiotics outside the cytosolic compartment [7, 23]. They have active sites that accommodate substrates of dissimilar structure and molecular size (300–2000 KDa) [24]. The majority of the substrates are amphipathic and have at least one aromatic ring attached to an amine group. Their amphipathicity enhances its binding affinity to P-gh as their hydrophobic part binds to the active sites that are embedded inside the membrane while the hydrophilic one binds to the sites exposed to the cytosolic compartment [25] (Figure 1).

Four ABC transporter proteins have been identified in *Plasmodium falciparum*, namely, *pfmdr 1* (*Plasmodium falciparum* multidrug resistance-1) [26, 27], *pfmdr 2* (*Plasmodium falciparum* multidrug resistance-2) [28], *pfmrp* (*Plasmodium falciparum* multidrug resistance associated protein) [29], *pf gcn20*, and *pf a0590w*.

Pfmdr-1 is ubiquitous on DV membrane and is involved in multidrug resistance through dispatching xenobiotics away of the cytosol [19]. In plasmodium, it acts as an auxiliary mechanism beside simple diffusion for drug entry into the DV.

Meanwhile, *pfmdr-2* is involved in translocation of heavy metals and has nothing to do with multidrug resistance [30, 31]. Nevertheless, some previous articles had related it to CQR and MQR (mefloquine resistance) [28].

On the other hand, *pfmrp* is present in cell membrane and membrane bound vesicles and is involved in the transport of glutathione and its conjugates. Meanwhile, biological functions of the last two have not been specified yet [29, 32].

3.1.1. Point Mutations in *Pfmdr-1*. *Pfmdr-1* point mutations were observed in both CQ resistant and susceptible strains of *Plasmodium falciparum*. They ablate the transporter capacity to drift drugs, namely, CQ, quinoline (QN), mefloquine (MQ), halofantrine (HF), and lumefantrine (LM), into the DV [33, 34]. The wild (nonmutant) form (*pfmdr-1*^{CQS}) mediates transfer of drugs, such as CQ, quinoline (QN), mefloquine (MQ), halofantrine (HF), and lumefantrine (LM), from the cytosol into the vacuole. Its ubiquity is prominent in MQ, HF, and LM resistant strains as it sways them away from their target site of action in the cytosol [21, 26].

Four plausible single nucleotide polymorphisms (SNPs) were detected in *pfmdr-1* gene, N86Y, N1042D, S1034C, and D1246Y [33, 35] in which asparagine at codons 86 and 1042, serine at codon 1034, and aspartic acid at codon 1246 of *pfmdr-1* protein had been replaced by tyrosine, aspartic acid, cystine, and tyrosine, respectively. These substitutions have altered P-gh physiochemical properties as all the substitute amino acids are more polar as compared to their substituent (as indicated by their hydrophobicity indices—Table 1) [36].

Each amino acid has certain physiochemical property, namely, side chain volume, side chain charge, and hydrophilicity index. Its substitution in the structure of any transporter changes the transporter physiochemical properties and consequently affects its potential to bind to and transfer different xenobiotic [37].

Distribution of *pfmdr-1* mutations is inconsistent over different geographic areas due to the discrepancy in the type of stress that each strain had experienced [38]. For instance, N86Y mutation disseminates widely in Asia and Africa while S1034C, N1042D, and D1246Y exist in South America.

3.1.2. Role of the Mutant *Pfmdr* Allele in Drug Resistance. Conflicting results were generated by studies that investigated the correlation between expression level of *pfmdr-1*^{CQR} and the extent of resistance to CQ or other quinoline antimalaria drugs. Earlier studies had revealed that genetic overexpression and protein amplification of the mutant forms of both *pfmdr-1* and *pfmdr-2* were significantly correlated to the degree of CQ resistance. Accordingly, scientists had concluded that both *pfmdr-1* and *pfmdr-2* induced multidrug resistance which is responsible for CQR in *Plasmodium falciparum* [28]. This conclusion was prejudiced when latter screening studies failed to prove that correlation [39] wherein




FIGURE 1: Detailed structure of P-glycoprotein molecule. It is made up of two domains: membrane domain (MD) that is embedded in the DV membrane and nucleotide binding domain (NBD) which faces the cytoplasm and mediates interaction with ATP. When ATP binds to NBD, conformational changes incur in the structure of the molecule resulting in rearrangement of the active sites of the MD domain in such a way that allows accommodation of the substrate molecules and their consequent engulfment throughout the DV membrane.

TABLE 1: List of plausible mutations in *pfmdr-1* of *Plasmodium falciparum* along with properties of both substituent and substituted amino acids.

Site of mutation	Substituted amino acids	Polarity	Side chain charge	Hydrophobicity index	Substituent amino acid	Side chain polarity	Side chain charge	Hydrophobicity index
86	Asparagine	Polar	Neutral	-3.5	Tyrosine	Polar	Neutral	-1.3
1042	Asparagine	Polar	Neutral	-3.5	Aspartic acid	Acidic polar	Negative	-3.5
1034	Serine	Polar	Neutral	-0.8	Cystien	Non polar	Neutral	2.5
1246	Aspartic acid	Acidic polar	Negative	-3.5	Tyrosine	Polar	Neutral	-1.3

less copies of *pfmdr-1*^{CQR} were detected in some CQ resistant strains [40, 41]. This led to a suggestion that *pfmdr-1*^{CQR} has a role in augmenting CQR but it is not the sole cause. This observation was proved by one cross-genetic study between HB3, a CQ susceptible strain of *Plasmodium falciparum*, and Dd2, a CQ resistant one. The study showed that transfection of *pfmdr-1*^{CQR} into the susceptible strain or *pfmdr-1*^{CQS} into the resistant strain does not produce a pronounced change in their response to CQ [39].

Furthermore, the majority of the survey studies revealed that there was no correlation between *pfmdr-1*^{CQR} ubiquity and CQR prevalence [34, 38, 41–44].

One epidemiological study that was run in Thailand had found that N86Y is not implicated in CQR as the team failed to find any correlation between its expression and spread of CQR within the screened areas [45]. On the other hand, allelic exchange experiments showed that replacement of these point mutations by wild genes increases susceptibility of the parasite to chloroquine as detected by [3] hypoxanthine incorporation experiments [46].

Eventually, it was concluded that presence of *pfmdr-1*^{CQR} is not provisional for CQR but may relate to fitness adaptations in response to the physiological changes that result from other genetic mutations that are most likely to be associated with *pfcr*. *Pfcr* is another transporting system which was discovered subsequently and is involved in conferring drug resistance. This phenomenon was proved by Reed et al. as the team found that introduction of S1034C, N1042D,

and D1246Y mutations through allelic exchange experiments into CQ susceptible strains of *Plasmodium falciparum* did not alter their response to CQ [20, 34, 46]. A similar cross-genetic study run by [47, 48] in which *pfmdr-1* alleles from each of 7G8, a CQ resistant strain present in Latin America (*pfmdr-1*^{7G8}), and D10 strain, a CQ sensitive strain of *Plasmodium falciparum* (*pfmdr-1*^{D10}), were transfected to the other strains reciprocally. The results showed that, in spite of its ability to alter CQ IC₅₀, *pfmdr-1*^{7G8} was insufficient to confer CQR in D10 while the wild *pfmdr-1*^{D10} allele could have halved CQR level in 7G8 without changing the parasite phenotype into CQ susceptible.

According to a study by Michael B. Reed, 1999 [48], altering *pfmdr-1* sequence in 7G8, which is sensitive to MQ, HF, to encode ser 1034, asn 1042, and asp 1246 through transfecting it with a wild form of *pfmdr-1* allele (*pfmdr*^{D10}), confers for higher resistance to these antimalarials. The most pronounced effect was seen after introducing a single tyr 1246 mutation as compared to that after introducing both asp 1042 and cyc 1034 SNPs. This highlights the importance of 1246 amino acid in the interaction with MQ and LM [47].

Emergence of K1HF strain after exposing K1H, a CQ resistant and HF susceptible cell line of *Plasmodium falciparum*, to HF pressure in study was another proof that CQR is not totally dependent on *pfmdr-1*. K1HF phenotype is alien to that of K1H such that it is CQ susceptible and HF sensitive. This change was not accompanied by any overexpression or sequence change in *pfmdr* [49].

It was found that amplification of the copy number of the wild form of *pfmdr-1* gene accounts for half of the recrudescence and treatment failure that occur after having selection pressure induced by mefloquine (MQ), lumefantrine (LM), and artemisinin (ART). This phenomenon is accompanied by enhancement in CQ susceptibility [50].

It is noteworthy that there is an interstrain difference in the copy number of *pfmdr-1* gene that it reaches its upmost values in both Dd2 and FCB strains of *Plasmodium falciparum*. This has an impact on sensitivity to some drugs, such as mefloquine and artemisinin [34].

Overall, *Plasmodium falciparum* strains that exhibit resistance to ART, HF, and/or MQ are characterized by having higher copy number of *pfmdr-1* allele and ubiquity of the well-known *pfmdr-1* mutations, namely, 86N, 1034S, 1042N, and 1246N. *Pfmdr-1* mutations selection may occur after exposure to MQ, ART, and/or HF.

3.1.3. *Pfmrp-1* (*Plasmodium falciparum* Multidrug Resistance Associated Protein). *Pfmdr-1* is not the only ABC transporter protein associated with CQR, but *pfmrp-1* (*Plasmodium falciparum* multidrug resistance associated protein) is another DV membrane protein concerned with CQ inflow into the DV [29]. Genetic survey studies revealed that *pfmrp* ability to drift CQ into the DV is afflicted by two point mutations, Y191H and A437S where tyrosine and alanine at codons 191 and 437 had been replaced by histidine and serine, respectively. The substitute amino acids are polar as compared to their substituent ones as indicated by their values of hydrophobicity index (Table 2). This posits the importance of polarity in the active sites of *pfmrp* for CQ binding. Due to its alkaline characteristics, histidine evolves a steric repulsion with quinine nucleus containing molecules. Although their ubiquity is not provisional for conferring CQ resistance, both of Y191H and A437S mutations play a role in augmenting the degree of CQ resistance [7, 32]. It is noteworthy that both Y191H and A437S mutations were reported in Dd2 strain which is highly resistant to CQ [51].

3.2. *Pfcr1* (*Plasmodium falciparum* Chloroquine Resistance Transporter) as an Essential Tool in Conferring Chloroquine Resistance. Later on, another protein was discovered on the surface of the DV membrane called *pfcr1* (*Plasmodium falciparum* chloroquine resistance transporter). It is a 48 KDa putative transporter or channel that belongs to DMT family of transporter proteins (drug metabolite transporter). It acts as an anion channel and mediates CQ efflux outside the DV. This role that has been studied extensively in lots of *in vitro* cross-genetic transfection studies ended up with controversial results. Some of them proved the dependency of CQR on *pfcr1* expression level while others failed [17, 52]. This discrepancy was first attributed to the inconsistency of the experimental conditions and the used strains [40]. Later on, this debate was solved as it was found that CQR is more related to point mutations in *pfcr1* gene rather than *pfcr1* expression level [53].

3.2.1. *Pfcr1* Structure. *Pfcr1* is made up of 424 amino acids arranged in 10 α -helical transmembrane domains (TDMs) oriented inside the DV membrane and N-termini which are exposed to the cytosol. TDMs contain active sites that mediate binding and translocation of substrates. Figure 2 shows the detailed structure of *pfcr1*. There is an internal symmetry between the first and second five TDMs such that TDMs 4 and 9 are responsible for binding and translocation of substrates. Both 3 and 8 assist in binding and translocation of the substrates and affect substrate specificity. TDMs 1, 2, 6, and 7 are responsible for identifying the substrates while 5 and 10 are responsible of homodimer formation.

3.2.2. *Pfcr1* Function. It is suggested that *pfcr1* performs several functions, such as efflux of alkaloids, amine compounds, divalent cations and amino acids, and peptides that result from the vacuolar digestion of globin. Furthermore, it is culminated to have a role in regulation of H^+ homeostasis [53].

3.2.3. *Pfcr1* Mutations and CQR. Most of the studies that were concerned about investigating the relationship between *pfcr1* and CQR are confounded by inaccuracies that stemmed from relying on one time dose response measurement and using polyclonal fresh clinical isolates [54].

Till now, 32 plausible point mutations have been identified in *pfcr1* gene. Their ubiquity alters *Pfcr1* physiochemical properties and the phenotype of the strain regarding CQ susceptibility [55].

3.2.4. Effect of Amino Acids Substitution on *Pfcr1* Physiochemical Properties. Any point mutation that alters amino acid sequence of any channel results in changing its physiochemical properties and functional characters. Each amino acid has certain distinguishing properties that determine its impact on the channel function, such as molar mass, van der Waals volume and V_r^e (average volume of buried residue), lipophilicity or hydrophobicity index, and isoelectric point [56]. These properties affect channel function through changing its side chain volume, negativity, and polarity. The first three amino acids properties are related to the tendency of the amino acid to create a bulky group that hinders passage of the entities through the channel. Van der Waals volume refers to an imaginary hard sphere that the molecule occupies. Meanwhile, V_r^e is related to the tendency of the amino acid to be buried inside the protein and is calculated from the area of its side chain. On the other hand, lipophilicity index is an index that refers to the ability of the amino acids to associate with lipophilic molecules. Meanwhile, isoelectric point (IP) refers to the pH at which the amino acid forms the zwitterion [56] (Table 3).

Normally, DV pH is maintained at narrow range which is more or less around 5. The majority of the mutations take place at the side that faces the cytosol. Accordingly, those amino acids, whose IP is more than 5, tend to impart positivity of for the channel. When IP value approaches or drops below than 5, higher channel negativity is conferred.

TABLE 2: List of mutations in *pfmrp* of *Plasmodium falciparum* along with properties of both substituent and substituted amino acids.

Site of mutation	Substituted amino acids	Side chain polarity	Side chain charge	Hydrophobicity index	Substituent amino acid	Side chain polarity	Side chain charge	Hydrophobicity index
191	Tyrosine	Polar	Neutral	-1.3	Histidine	Basic polar	Partially positive	-3.2
437	Alanine	Non polar	Neutral	1.8	Serine	Polar	Neutral	-0.8




FIGURE 2: Detailed structure of *pfcr*t protein. It is made up of 422 amino acids distributed over 10 transmembrane domains. Inside the structure there are 32 candidate codons for having point mutations that confer for changing *pfcr*t function. The majority of them occur at the site that faces the DV media. Binding of substrates to *pfcr*t does not require ATP activation as in P-glycoprotein molecules.

Consequently, this affects CQ exodus outside the channel [57].

3.2.5. K76T Mutation. In K76T mutation, the neutral threonine replaces the positively charged lysine residue at codon 76 in the structure of *pfcr*t [58, 59]. It is a marker of CQR as its ubiquity is provisional to confer CQ resistance [60]. In contrary, there are few exceptions wherein, in spite of presence of K76T, the parasite is CQ susceptible. This is due to coexistence of other unique mutations that obviate K76T effect [61]. As an exception, J9 strain, which is found in Thailand, has got K76A mutation in which alanine is present instead of threonine at codon 76 [18].

Lysine replacement by threonine at codon 76 imparts for higher lipophilicity and negativity in *pfcr*t lining and reduces the side chain volume. These changes favor egress of the ionized fraction of CQ (CQH^+ & CQH_2^{++}) outside the DV [62]. Due to its positive charge, lysine hampers egress of CQ through repulsing the positively charged ionized CQ molecule. Moreover, it has a bulkier side chain compared to threonine which hinders CQ egress. Furthermore, this change increases the size of the hydrophobic sites which are

required by CQ to bind into the channel before it egresses out. Accordingly, the majority of the scientists favored the third hypothesis to interpret the role of K76T mutation in conferring CQR [60].

Discovery of 106/I clone of *Plasmodium falciparum* is a clear evidence of the importance of K76T mutation in conferring CQR as this strain contains 6 out of 7 well-known mutations that are consistently present in the CQ resistant cohorts except for K76T. Absence of K76T turned 106/I to a CQ susceptible parasite [62, 63].

K76T mutation is primarily and completely selected after long term exposure to CQ. On the other hand, its ubiquity is not correlated with LM, HF, ART, and MQ susceptibility. This discrepancy is due to the disparity of the mechanism through which resistance to each of these drugs develop [64].

3.2.6. Other Corollary *Pfcr*t Mutations. After discovering K76T mutation, other nonsilent point mutations were discovered in loci: 19, 58, 72, 74, 75, 90, 97, 101, 123, 140, 146, 148, 152, 160, 163, 194, 198, 205, 220, 251, 271, 275, 277, 326, 327, 333, 334, 356, 371, 350, and 352 (Tables 4 and 5) [54]. Rapid

TABLE 3: Physiochemical properties of different amino acids.

Amino acid	Code	Formula	Molar mass	Van der Waals volume	V_r^e/A^3	Polarity	Acidity	Hydropathy index	Isoelectric point (pI)
Alanine	Ala/A	C ₃ H ₇ NO ₂	89.09	67	92	Nonpolar	Neutral	1.8	6.01
Arginine	Arg/R	C ₆ H ₁₄ N ₄ O ₂	174.2	148	225	Polar	Basic (strong)	-4.5	10.76
Asparagine	Asn/N	C ₄ H ₈ N ₂ O ₃	132.11	96	135	Polar	Neutral	-3.5	5.41
Aspartic acid	Asp/D	C ₄ H ₇ NO ₄	133.1	91	125	Polar	Acidic	-3.5	2.85
Cysteine	Cys/C	C ₃ H ₇ NO ₂ S	121.15	86	106	Polar	Neutral	2.5	5.05
Glutamic acid	Glu/E	C ₅ H ₉ NO ₄	147.13	109	161	Polar	Acidic	-3.5	3.15
Glutamine	Gln/Q	C ₅ H ₁₀ N ₂ O ₃	146.15	114	155	Polar	Neutral	-3.5	5.65
Glycine	Gly/G	C ₂ H ₃ NO ₂	75.06	48	66	Nonpolar	Neutral	-0.4	6.06
Histidine	His/H	C ₆ H ₉ N ₃ O ₂	155.15	118	167	Polar	Basic (weak)	-3.2	7.6
Isoleucine	Ile/I	C ₆ H ₁₃ NO ₂	131.17	124	169	Nonpolar	Neutral	4.5	6.05
Leucine	Leu/L	C ₆ H ₁₃ NO ₂	131.17	124	168	Nonpolar	Neutral	3.8	6.01
Lysine	Lys/K	C ₆ H ₁₄ N ₂ O ₂	146.18	135	171	Polar	Basic	-3.9	9.6
Methionine	Met/M	C ₅ H ₁₁ NO ₂ S	149.2	124	171	Nonpolar	Neutral	1.9	5.74
Phenylalanine	Phe/F	C ₉ H ₉ NO ₂	165.19	135	203	Nonpolar	Neutral	2.8	5.49
Proline	Pro/P	C ₅ H ₉ NO ₂	115.13	90	129	Nonpolar	Neutral	-1.6	6.3
Serine	Ser/S	C ₃ H ₇ NO ₃	105.09	73	99	Polar	Neutral	-0.8	5.68
Threonine	Thr/T	C ₄ H ₉ NO ₃	119.12	93	122	Polar	Neutral	-0.7	5.6
Tryptophan	Trp/W	C ₁₁ H ₁₂ N ₂ O ₂	204.22	163	240	Nonpolar	Neutral	-0.9	5.89
Tyrosine	Tyr/Y	C ₉ H ₉ NO ₃	181.19	141	203	Polar	Neutral	-1.3	5.64
Valine	Val/V	C ₅ H ₁₁ NO ₂	117.14	105	142	Nonpolar	Neutral	4.2	6

diagnostic assays for *pf*crt mutations are already employed as surveillance tools for drug resistance [65].

Various patterns of genetic mutations occur in different geographic areas due to the disparity in the condition that the parasite experiences. Majority of them occur at codons 72, 74, 75, and 76 (Table 4) [66]. These variations result in lots of structural polymorphic changes in *pf*crt with appearance of several haplotypes with different degree of CQ resistance, CQ resistance by VPL and other reversing agents [17], and susceptibility to other antimalaria drugs.

It was found that eleven out of the total 32 polymorphic residues are associated with CQR, such as M74I, N75E, K76T, H97Q, A220S, Q271E, N326S, I356T, C350S, and R371I R. At least another three mutations are required along with K76T to confer CQ resistance [18] (Tables 4 and 5).

Various *pf*crt mutations are found in different geographic loci. This discrepancy is attributed to the difference in the history of the drug use in different places which result in evolution of alternate sets of *pf*crt mutations [67, 68] (Tables 4 and 5).

Genetic studies, which had screened the CQR related genetic foci and chromosomal markers in different geographic areas, found that *Plasmodium falciparum* strains isolated from Southeast Asia and Africa (old world strains) have quite similar major resistance to foci. On the other hand, the strains in each of South America and Papua New Guinea (new world strains) strains arose independently and each one has its own drug resistance genetic foci [69, 70]. Tables 6 and 7 contain a list of the most famous CQ resistant and susceptible strains and their geographic distribution.

VPL induced CQ resistance reversibility is more pronounced in old world strains (Dd2 and K76I) while it is absent in South American ones, namely, 7G8. Scientists had attributed this to the ability of VPL to interact with *pf*crt of the former and its failure to do so with the latter [59].

The majority of the effective mutations (Tables 4, 6, and 7) occur in the region between codons 72 and 76. This had resulted in evolution of different genotypic sequences, namely, CVMNK, CVIET, and SVMNT, which consequently produce different phenotypes with different aptitude to confer CQR (Tables 4, 6, and 7). CVMNK is a characteristic feature of CQ susceptible parasites. Both CVIET and SVMNT are found in CQ resistant strains of *Plasmodium falciparum*. The former is distributed in Southeast Asia and the latter is found in Africa (Tables 6 and 7). Other mutations are found in loci distant from (72–76) region, namely, 97, 220, 271, 326, 356, and 371 (Tables 5, 6, and 7).

In the absence of K76T mutation, the other corollary mutations start affecting CQ response to a certain extent. Bayomi et al. found that CQ response in 106/I is less as compared to other CQ susceptible strains. The team attributed this to the presence of the other corollary mutations in *pf*crt that may impart for less CQ accumulation in the DV. Although 106/I harbors the mutant *pf*mdr-1, it does not impart for the reduced CQ response [63], such that, in one cross-genetic study, it was found that replacing the mutant *pf*mdr-1 allele in 106/I by *pf*mdr-1^{D10} allele, the wild *pf*mdr-1 subtype, or by any other wild *pf*mdr-1 allele did not produce any change in CQ susceptibility [71].

TABLE 4: List of the plausible mutations that may occur in *pfcr*t within the regions 72–76 along with their geographic distribution, effect on channel physiochemical properties, and their impact on the phenotype of the parasite toward chloroquine resistance.

Mutation	Geographic distribution	Effect on channel negativity	Effect on side chain volume	Effect on the channel lipophilicity	Overall effect on chloroquine resistance and VPL induced reversal of CQ resistance
C72S	CQ resistant strains of the new world	High increase		Decrease	Imparts for non VPL reversible CQ resistance
N74I	Old World CQ resistant strains	High increase		Increase	Imparts for VPL reversible CQ resistance
N75D	Cambodian CQ resistant strains	Increase	Decrease		Imparts for higher CQR without affecting VPL binding
N75E	Old World CQ resistant strains	Increase		No effect	Imparts for higher CQR without affecting VPL binding
K76N	Long term exposure of 106/I strain to CQ	Increase			Imparts for VPL reversible CQR with IC_{50} of about 12-folds that of 106/I. On the other hand, it imparts for higher MQ, HF, LM, and DHA activity
K76I	Long term exposure of 106/I strain to CQ	Increase			Imparts for higher CQR with IC_{50} of about 12-folds that of 106/I. On the other hand, it imparts for higher MQ, HF, LM, and DHA activity

TABLE 5: List of some famous mutations in *pfcr*t in foci far from 72 to 76 regions along with their geographic distribution, effect on channel physiochemical properties, and their impact on the phenotype of the parasite toward chloroquine resistance.

Mutation	Geographic distribution	Effect on channel negativity	Effect on side chain volume	Effect on the channel lipophilicity	Overall effect on chloroquine resistance and VPL induced reversal of CQ resistance
H97Q	Only in TM90-6CB, the Thai CQ resistant strain	Increase		No effect	Imparts for higher CQ resistance without affecting VPL binding
A220S	All CQ resistant strains	Increase		Decrease	Impart for non-VPL reversible CQ resistance
Q271E	Old World CQ resistant strains and the CQ susceptible strains derived from KH1 strain	Increase			Imparts for higher CQ resistance without affecting VPL binding
N326S	Old World CQ resistant strains and the CQ susceptible strains derived from KH1 strain			Increase	Imparts for reversibility of CQ resistance by VPL
I356T	Some CQ resistant strains in Southeast Asia, namely, Dd2, BC7, BC22, KS28, and 738	Increase	Decrease	Decrease	Impart for non-VPL reversible CQ resistance (it explains why VPL reversibility is higher in K1 rather than in Dd2)
I356L	New World CQ resistant strains	Little increase		Little increase	Imparts for higher CQ resistance and VPL induced reversibility of CQ resistance
R371	Old World CQ resistant strains and the CQ susceptible strains derived from KH1 strain			Increase	Impart for VPL induced reversibility of CQ resistance

3.2.7. *Relationship between Pfcr*t and *Pfmdr*-1 Alleles. CQ resistant strains of *Plasmodium falciparum* possess codon mutations that alter *pfcr*t structure along with microsatellite polymorphs that flank *pfcr*t structure. CQ resistance mediated by the mutant *pfcr*t is either modulated by another

gene, which is *pfmdr*-1 gene that is linked to change of IC_{50} values of some strains, or by factors that create a physiological environment that prevent *pfcr*t of exerting its full capacity of CQ resistance induction. Several cross-genetic and epidemiology studies run in Africa, Southeast Asia, and Oceania

TABLE 6: List of chloroquine sensitive strains of *Plasmodium falciparum* along with their geographic distribution and both *pf*crt and *pf*mdr-1 haplotypes.

Strain	Geographic distribution	<i>Pf</i> crt haplotype																				<i>Pf</i> mdr-1							
		72	74	75	76	77	97	123	144	148	152	160	163	194	198	205	220	271	275	277	326	333	350	356	371	86	184	1034	1042
D7 (wild type)	Southeast Asia and Africa	C	M	N	K	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	N	T	C	I	R	N	Y	S	N	D
HB3	Honduras	C	M	N	K	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	N	T	C	I	R	N	Y	S	D	D
GC03	Genetic-cross studies of Dd ₂ and HB ₃	C	M	N	K	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	N	T	C	I	R	N	Y	S	N	D
MP2475	Malaysia	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	Y	S	N	D	
MP2533	Malaysia	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	F	S	N	D	
N29.07	Africa (Nigeria)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	F	S	N	D	
N60 and N92	Africa (Nigeria)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	Y	S	N	D	
Th230.08	Africa (Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	Y	S	N	D	
Tg060.07	Africa (Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	F	S	N	D	
P09.04 and P19.04	Africa (Pikine/Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	Y	S	N	D	
P31.01 and P08.04	Africa (Pikine/Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	N	F	S	N	D	
P11.02	Africa (Pikine/Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	S	T	I	I	N	F	S	N	D	
P27.02	Africa (Pikine/Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	A	A			N	N	T	I	I	Y	F	S	N	D	
P60.02	Africa (Pikine/Senegal)	C	M	N	K	H	H	A	L	L	L	I	E	T	S	S			N	N	T	I	I	N	F	S	N	D	
K1 AM	Positive selection of KIH with amantadine	C	I	E	T	H	H	A	L	T	L	R	I	E	T	S	E	P	N	S	T	C	V	I					
K1 HF	Positive selection of KIH with HF	C	I	E	T	H	H	A	L	A	L	R	I	E	T	S	E	L	N	S	T	C	I	I					
Pf164	Southeast Asia	C	I	E	T	H	H	A	L	T	L	R	I	E	T	S	E	P	N	S	T	C	I	I					
106/I	Sudan (Awad-el-Kariem FM 1992)	C	L	E	K	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	I	I					
D10	Papua New Guinea	C	M	N	K	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	N	T	C	I	R	N	Y	S	N	D
D6	Sierra Leone	C	M	N	K	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	N	T	C	I	R	Y	Y	S	N	D
NF54		C	M	N	K	H	H	A	L	L	L	I	E	T					N	N	T	T			N	Y	S	N	D
H209	French Guinea	S	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	R	L	R					

TABLE 7: List of chloroquine resistant strains of *Plasmodium falciparum* along with their geographic distribution and both *pf*crt and *pf*mdr-1 haplotypes.

Strain	Geographic distribution	CQR reversal by VPL	Pfcrt haplotype																											Pfmdr-1					
			72	74	75	76	97	123	144	148	152	160	163	194	198	205	220	271	275	277	326	333	350	356	371	86	184	1034	1042	1246					
CQ resistant strains																																			
<i>K1H</i>	Southeast Asia (Thailand)	✓	C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	I	I	I									
<i>J9</i>	Southeast Asia (Thailand)	✓	C	I	E	A	H	H	A	L	T	L	S	I	E	T	S	E	P	D	S	T	C	I	I	I									
<i>BC7</i>	Thailand		C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	T	I	I									
<i>BC22</i>	Thailand		C	I	E	T	H	H	A	L	T	L	S	I	K	T	S	E	P	N	S	T	C	T	I	I									
<i>KS28</i>	Thailand		C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	T	I	I									
<i>Dd2</i>	Southeast Asia (Indochina and Laos)	✓	C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	T	I	I									
<i>K76I (J34)</i>	Southeast Asia		C	I	E	I	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	C	I	I	I									
<i>PHI</i>	The Philippines	✓	C	M	N	T	H	H	T	L	T	Y	S	I	E	T	A	Q	P	N	D	T	C	I	R	I									
<i>PH2</i>	The Philippines		S	M	N	T	H	H	T	L	T	Y	S	I	E	T	A	Q	P	N	D	T	C	I	R	I									
<i>738</i>	Cambodia		C	I	D	T	H	H	A	I	T	L	S	T	E	T	S	E	P	N	N	T	S	I	R	I									
<i>734</i>	Cambodia		C	I	D	T	H	H	A	I	T	L	S	T	E	T	S	E	P	N	N	T	S	I	R	I									
<i>783</i>	Cambodia		C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	D	T	S	T	I	I									
<i>TM90-6CB</i>	Thailand	✓	C	I	E	T	Q	H	H	A	L	L	S	I	E	T	S	E	N	N	S	T	I	I	I	N	F	C	D	Y					
<i>TM6</i>	Thailand		R	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L				
<i>TM93-C1088</i>	Thailand		H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L				
<i>2300</i>	INDONESIA		C	I	K	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	S	T	S	I	I	I									
<i>PNG4</i>	PNG		S	M	N	T	H	H	A	L	T	L	S	I	E	T	A	Q	P	N	D	T	C	L	R	I									
<i>APO41</i>	Africa (Nigeria)	✓	C	I	E	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	F	S	N	D					
<i>N60</i>	Africa (Nigeria)	✓	C	I	E	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	Y	S	N	D					
<i>N62</i>	Africa (Nigeria)	✓	C	I	E	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	Y	F	S	N	D					
<i>P05.02 and P51.02</i>	Africa (Pikine/Senegal).	✓	C	I	E	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	Y	F	S	N	D					
<i>P26.02</i>	Africa (Pikine/Senegal)	✓	C	I	E	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	Y	F	S	N	D					
<i>GB4</i>	Ghana		C	I	E	T	H	H	A	L	T	L	S	I	E	T	S	E	P	N	N	T	S	I	R										
<i>7G8</i>	South America (Brazil)	X	S	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	C	L	R	N	F	C	D	Y					
<i>J3D4</i>	South America	X	S	M	N	T	H	H	A	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	F	S	D	Y					
<i>G209</i>	South America	X	S	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	C	L	R	N	F	S	D	Y					
<i>G224</i>	South America		S	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	C	L	R	N	F	S	D	Y					
<i>TU741</i>	Colombia		C	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	N	L	L	R									
<i>JAV</i>	Colombia		C	M	E	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	N	T	S	I	T	T									
<i>TA7519</i>	Colombia		C	M	E	T	Q	H	A	L	T	L	S	I	E	T	S	Q	P	N	N	T	S	I	T	T									
<i>TA6182</i>	Colombia		C	M	E	T	Q	H	A	L	T	L	S	I	E	T	S	Q	P	N	S	T	S	I	T	T									
<i>ECUIH0</i>	Ecuador		C	M	N	T	H	H	A	L	T	L	S	I	E	T	S	Q	P	N	D	T	S	L	R										

proved this impact. This relationship was proved in a cross-genetic study between clones from Brazil and Ghana, 7G8 and GB4 [72]. Response to CQ and AQ and to their respective metabolites, MDCQ (monodesethyl chloroquine) and MDAQ (monodesethyl amodiaquine), was measured with different *pfmdr-1* and *pfcr*t alleles. The study showed that *pfcr*t allele is the major determinant in their response and the mutant alleles of *pfmdr-1* can merely modulate the degree of resistance in the strains that express the mutant allele of *pfcr*t. The study showed the importance of coexistence of *pfmdr-1*^{7G8} along with *pfcr*t^{7G8} to confer higher degree of resistance to CQ, AQ, and their metabolites. Transfecting *pfmdr-1*^{GB3} allele to 7G8 strains reduces resistance to these drugs. The study determined contribution of each of 7G8 *pfmdr-1* mutations, 1034C, 1042D, and 1246Y in conferring CQR and AQR. It was found that 1042D has the major contribution in imparting moderate CQR, poor sensitivity to VPL, and high degree of AQR. In a study of CQR and AQR in PGN isolates, lots of CQR isolates were obtained carrying a *pfcr*t with SVMNT genotype. Degree of their CQR is lower in the isolates that carry neither 86Y nor 1042D mutations in *pfmdr-1* allele [72].

WHO graded resistance to early treatment failure, late treatment failure, or inadequacy of clinical and physiological response. Prevalence of treatment failure or drug resistance is concomitant with K76T and is augmented when *pfmdr-1*^{N86Y} allele coexists [73].

3.2.8. Functional Role of *Pfcr*t Mutation. Mutations in certain active foci of *pfcr*t result in changing its aptitude to pump CQ and other drugs outside the DV and regulate the intravacuolar pH. Furthermore, it affects the ability of verapamil (VP) or other drugs to reverse CQ resistance [69].

*Pfcr*t acts as an ion channel that regulates the electrochemical potential across the DV membrane and regulates egress of the ionized drugs [74]. On the other hand, *pfcr*t is related to V type ATPase enzyme. An enzyme is present in various organelle membranes and is involved in pumping of protons into the organelles.

3.2.9. Regulation of DV pH and Effect of *Pfcr*t Mutation on Intravacuolar pH. DV acidity is attributed to the ingress of H⁺ through V-type-ATPase [75] and H⁺-pyrophosphatase mediated H⁺ pump mechanisms [76]. DV alkalinization is attained by inhibiting of the former by concanamycin A or bafilomycin A1 and the latter by NaF [76]. H⁺ accompanies CQ while the latter is pumped outside the DV. The intravacuolar localization of chloroquine gives rise to a substantial leakage of H⁺ outside the DV in CQ resistant unsusceptible strains [77].

PH dependency of CQ-heme interaction confers for the importance of alkalinization to reverse CQR. If the reversal agent fails to alkalinize DV and promote exodus of H⁺, then reversal of the resistance fails to proceed.

Presence of the mutant *pfcr*t in CQ resistance strains of *Plasmodium falciparum* is accompanied by a decrease in the intravacuolar pH [77, 78]. In one study, after transfecting a *pfcr*t gene into an oocyst of *Xenopus laevis*, there was

a significant rise in the intracytosolic and reduction of DV pH values due to role of *pfcr*t in pumping H⁺ outside the DV [77, 78]. Meanwhile, other studies found that *pfcr*t acts as a Cl⁻ channel and this augments its role in maintaining intravacuolar pH [70].

3.2.10. *Pfcr*t Mutations and Verapamil (VPL) Reversibility of CQ Resistance (Verapamil Effect (VE)). CQR reversal by verapamil (VPL) became another hallmark of CQR in the resistant strains of *Plasmodium falciparum*. Abundance of the hydrophobic sites in *pfcr*t structure increases the chance of VPL-induced CQR reversal. VPL binds to the hydrophobic sites and acts as a bulky group preventing egress of CQ outside the cell. The bound verapamil can replace the lost lysine during the mutation and acts as a repulsing moiety for CQ [79].

Scientists started to investigate the correlation between any of the abovementioned channel physiochemical characters (see Section 3.2.3) and parasite susceptibility to CQ and DCQ (desethylchloroquine) and VE. The results were quite controversial as some could not find any correlation and they attributed the phenomena to factors related to spatial orientation of the active sites within the channel. Others found a correlation between side chain volume of the channel lining and susceptibility to CQ or DCQ and between hydrophobicity of the channel and VPL induced CQR reversal. This suggests that CQR requires presence of bulky groups within the channel that act as obstacles preventing CQ exodus outside the DV. On the other hand, VP induced reversal of CQR required presence of hydrophobic sites where VP bind and prevent exodus of CQ [80].

4. Chloroquine (CQ) Resistance as a Continuous Trait with Multifactorial Inheritance

Ubiquity of the mutant form of *pfcr*t confers for higher CQR with an extent depending on the presence of other genetic loci [80]. It was found in a cross-genetic study between 3D7 (CQ susceptible strain in Southeast Asia) and 7G8, a South American CQ resistant strain of *Plasmodium falciparum*, that transfection of the mutant *pfcr*t into the CQ susceptible parasite confers for higher CQ resistance in that parasite. However, the extent of resistance in the transfected parasite did not match with the CQ resistant strain. Nevertheless, this phenomenon does not imply to all CQ susceptible strains as performing the same transfection on D10 strains did not produce any change in CQ IC₅₀ of the transfected parasite. On the other hand, expression of *pfcr*t^{7G8} in both 3D7 and D10 had conferred for higher resistance to MDCQ (monodesethyl chloroquine). Interestingly, both CQ and MDQ (monodesethyl chloroquine) resistances after the transfection were VPL reversible. Nevertheless, VPL reversibility is absent in the Latin American strains of *Plasmodium falciparum*. This suggests that introduction of *pfcr*t^{7G8} allele to other CQ sensitive strains may produce a VPL irreversible phenotype of CQ resistance. This suggests that VPL, as a calcium channel blocker, induces intracellular physiological changes

in the VPL sensitive strains resulting in change of *pfcr*t function and thence VPL reversibility of CQR. This point requires further investigation to find the precise effect of VPL in both Latin American and Southeast Asian strains of *Plasmodium falciparum* [81].

Mutant *pfcr*t allele introduction does not merely change CQ IC₅₀; it changes the slope of dose response curve with an evidence of continued growth at higher concentration. This effect is particularly pronounced after introducing *pfcr*t^{7G8} allele to D10 (D10^{pfcr7G8}). This change had generated a phenotype characterized by high CQ tolerance which is indicated by CQ IC₉₉ or IC₉₉ values. Recrudescence is another mode of treatment failure as it was found that 50% of the *in vitro* cultures recrudescence after 6 days of CQ discontinuation. Introduction of *pfcr*t^{7G8} allele to 3D7, D10, and GCO3 has raised level of recrudescence after CQ discontinuation. This suggests that the mutant allele of *pfcr*t confers for tolerance as well as for resistance.

Fitness cost is another phenomenon related to long term discontinuation of the antimalaria drug. It was found that some resistant strains of *Plasmodium falciparum* revert to CQ susceptible ones after removal of the selection pressure. For instance, in Malawi, Dd2 strains lost their *pfcr*t^{dd2} after drug discontinuation.

Detection of G224 and H209 in French Guinea isolates provides indisputable evidence that K76T is insufficient alone to confer CQR. Both G224 and H209 have got *pfcr*t and *pfmdr* haplotypes identical to that of 7G8 with only difference of *pfmdr*-1 at codon 1034 of *pfmdr* and codon presence of C350R mutation in H209. Western blot analyses did not detect any difference in the copy number of *pfcr*t allele. CQ activity screening study showed that these changes turned both G224 and H209 to CQ sensitive parasites as their IC₅₀ values were comparable to that of CQ sensitive strains and less than that of 7G8. On the other hand, analysis of CQ dose response curve revealed a skew in CQ IC₉₀ for both G224 and H209 toward that of 7G8. Furthermore, unlike other CQ sensitive strains, both G224 and H209 showed a comparable degree of recrudescence to that of 7G8. It was found that charge substitution at position 350 in *pfcr*t was selected by QN pressure in CQ resistant cell line. It was accompanied by reversion of the cell line into CQ susceptible one. H209 shows higher level of resistance to QN and ART as compared to G224 and 7G8.

5. Effect of *Pfcr*t and *Pfmdr*-1 on Other Antimalaria Drugs

5.1. Effect on Amodiaquine (AQ). Previous screening and cross-genetic *in vitro* studies showed that unlike CQ, amodiaquine (AQ) efficacy was not affected by the presence of any mutant form of *pfcr*t. First this had suggested that certain structural features present only in CQ are required for drugs to bind to *pfcr*t. Nevertheless, scientists found that AQ action *in vivo* is poorly correlated with its action *in vitro*. *In vivo*, AQ is metabolized to desethylamodiaquine (DAQ), an active metabolite to which the discrepancy in AQ action is attributed [80].

Unlike AQ, DAQ action is affected by ubiquity of the mutant form of *pfcr*t. Presence of K76T mutation in *pfcr*t facilitates escape of DAQ outside the digestive vacuole or its access to the 72–76 region of *pfcr*t structure. This is due to loss of the lysine residue that adds the due positivity which is required to prevent exodus of positively charged 4-aminoquinoline moieties. Moreover, DAQ exodus was correlated to presence of VE or presence of higher hydrophobicity in the 72–76 regions of *pfcr*t. *Pfcr*t channel hydrophobicity especially at the regions 72–76 and VE is highly prominent in the Asian Old World strains of *Plasmodium falciparum* in comparison to the New World South American ones. Leaked DAQ molecules tend to bind to such hydrophobic sites creating a bottleneck that prevent exodus of further molecules. This characteristic makes DAQ susceptibility highly correlated with hydrophobicity of *pfcr*t channel in the resistant strains of *Plasmodium falciparum*. Consequently, DAQ resistance is seen in the New World resistant strains of *Plasmodium falciparum* and is absent in the Old World ones [80].

5.2. Effect on Amantadine Action. Amantadine AM, an antiviral drug used for treatment and prophylaxis of influenza A virus infection, showed an anti-*Plasmodium* effect which is quite variable among different strains of *Plasmodium falciparum*. The action was more pronounced against the Asian strains Dd2 and J3D4, intermediate against the American strain 7G8, and nearly negligible in CQ sensitive strains [61, 82].

It was found that AM blocks M2 ion channels which is one of the viral envelope proteins that affects viral replication through regulation of H⁺ ingress into the virion after its endocytosis by the host cell. Point mutations that result in AM resistance was detected in M2 channels of influenza A virus. This suggests that AM may have an effect on the electrochemical gradient and proton pump of DV membrane [83, 84]. The studies revealed that *pfcr*t and its K76T mutation do not merely have a determinant role on the differential pattern of CQ susceptibility but they have as much important role on that of amantadine as well [61, 84].

In Singh Sidhu et al.'s 2002 study, the endogenous *pfcr*t allele of GCO3 was replaced by various *pfcr*t^{CQR} alleles, such as those of Dd2, J3D4(K76I) and 7G8, to get recombinant clones that contain all genetic materials of GCO3 along with one of the *pfcr*t^{CQR} alleles. The clones were different from the parent GCO3 strain as their degree of CQR was comparable to that of the original resistant cell lines that bear the transfected *pfcr*t^{CQR} alleles [53]. Aftermath, several studies found that as these clones develop higher resistance to CQ, they develop higher susceptibility to other drugs as MQ, HF, and AM as well. This confirms that the degree of AM susceptibility is highly dictated by *pfcr*t mutation. One of the plausible annotations of this is that expression *pfcr*t^{CQR} on the surface of DV results in higher exodus of alkaline drugs outside the vacuole and this raises their intracytosolic concentration and lowers their concentration in DV. It is noteworthy to note that all of the abovementioned drugs are weak alkaline. Their nonionized fraction permeates into the vacuole by simple

diffusion and once they reach the acidic milieu of DV, they ionize and trap there. *pfcr*^{CQR} alleles excrete them outside the vacuole resulting in either more intensified action if the drug target is in the cytosol or weaker action if it is in DV. MQ, HF, and AM targets are located in the cytosol so *pfcr*^{CQR} intensifies their action while CQ target is located in the DV so *pfcr*^{CQR} confers for its resistance [85, 86].

Along with three-month intermittent exposure of K1H6/2 strain, which harbors the same Dd2 *pfcr*^{CQR} allele, to AM, AM resistance had been developed in a stepwise manner along with parallel improvement in CQ susceptibility [3] and without any effect on both HF and MQ susceptibility. Aftermath, this phenotype was dubbed as KIAM and the genetic sequence and expression level of its *pfcr* and *pfmdr* alleles were studied extensively. It was revealed that the mutational changes in KIAM were not related to *pfmdr* as neither mutational change nor change in expression level had been detected [87]. Interestingly, in spite of presence of both K76T and A220S mutations, KIAM was CQ susceptible. It is considered as the first validated example of CQ susceptible *Plasmodium falciparum* cell line expresses both of these mutations. DNA sequencing studies revealed two novel mutations in the *pfcr* allele of KIAM strain, S163R and I356V. The former is unique to KIAM as it has never been reported in any *Plasmodium falciparum* but the latter was detected in some strains and was culminated as a culprit for development of CQR [87, 88].

Bray et al. 2000 studied the effect of AM on CQR in K1H6/2 strain. They found that along with its anti-Plasmodium effect against CQ resistant cell lines of *Plasmodium falciparum*, AM has a dichotomous relationship with CQ. From one side, it acts as VPL as it reversed VPL reversible CQR in K1H6/2 strains and from the other side its intermittent use on K1H6/2 induces mutational changes that invert CQR and convert the strain into KIAM strain [89].

5.3. Relationship of CQR and Mefloquine Action. It was noted that CQ action contravenes that of MQ in most strains of *Plasmodium falciparum*. MQ susceptibility is higher in CQ resistant strains and vice versa. Scientists attributed this either to the discrepancy in the location of their target sites as MQ target is located in the cytosol while CQ's is localized in the DV or to the plausible direct effect of both of *pfcr* or *pfmdr* on MQ. Direct action of *pfcr* on MQ was excluded as it was found that MQ does not affect efflux of H⁺ from *pfcr*. Unlike CQ resistance, MQ resistance is more affected by *pfmdr*-1 rather than *pfcr* mutation [90]. Moreover, it is correlated with amplification of the wild form of *pfmdr*-1 that mediates MQ accumulation inside the DV. On the other hand, MQ susceptibility is either associated with *pfmdr*-1 deamplification or overexpression of *pfmdr*-1^{CQR}. Furthermore, MQ resistance contravenes CQR that it is conferred by mutant form of *pfmdr* while *pfcr* just modifies it [90, 91].

S163R mutation rose independently in resistance selection experiments using HF or AM on K1H6/2 strains. It was detected in one CQ susceptible isolate that is dubbed aftermath as *pf163* during a screening study for its ubiquity

in 44 different geographic areas. Aftermath, through DNA sequencing studies, genetic sequence of *pfcr* allele of *pf163* was compared with that of other plasmodium strains. It was found that all of its codons were quite similar to those of K1H6/2 strain except codon 163 which exhibits S163R mutation. This augments the notion that S163R mutation obviates CQ resistance in CQ resistant strains of *Plasmodium falciparum* [87, 88].

MQ resistance aroused prominently in the Cambodian-Thai and Thai-Mynamar borders during the last 10 years. Genotype mapping in these areas failed to find any correlation between MQ resistance and prevalence of K76T polymorph of *pfcr*. This suggests that MQR develops in a mechanism distant from that of CQ resistance [92].

5.4. Effect on Phenanthrenes. Halofantrine HF and lumefantrine (LM) are the two substituted phenanthrene classes of antimalaria compounds. Their precise mechanism of action has not been identified yet but it is suggested that they bind to hematin and to plasmepsin (hemoglobin degrading enzyme) [93].

K1HF strain is an experimental strain obtained by exerting a selection pressure of HF on K1H6/2 strain. *In vitro* intermittent exposure of K1 cell line to HF results in higher resistance to MQ and HF and loss of CQR. This strain does not show any mutational change in *pfmdr* allele while a prominent change is seen in *pfcr*. *Pfcr* keeps both K76T and A220 S mutations but it gains other unique ones, such as T152A, S163R, and P275L. The scientists attribute most of the changes in CQ susceptibility to S163R as it was expressed in KIAM and both of them possess the same phenotypic pattern regarding CQ susceptibility in two independent experiments [94].

LM is mostly given in combination with artemether (ART) (AL-treatment) under a trade name Coartam. Coartam has been used extensively in Africa due to high spread of CQ resistance. According to a study in Kenya, which had investigated the relationship between the *in vitro* susceptibility of different antimalarials with different *pfcr* and *pfmdr* polymorphs, susceptibility of *Plasmodium falciparum* to LM is inversely proportional to that of CQ with a significant correlation. Furthermore, expression of wild type of *pfcr* and *pfmdr*, which are known for imparting higher CQ susceptibility, suppresses LM susceptibility [95].

It was found that long term exposure to LM may select for more CQ susceptible and LM resistant strains as it selects for the wild type of *pfmdr*-1 and increase its copy number. Emergence of LM resistance is more pronounced in the strains harboring the wild form of *pfcr* along with the wild form of *pfmdr*-1 [87]. It is noteworthy to dictate that such genotype is highly susceptible to CQ and this suggests the inverse relationship between CQ and LM. The rate of LM resistance emergence may occur rapidly. Unlike CQ, previous cross-genetic and transfection studies revealed that expression of the mutant *pfcr* in *Plasmodium falciparum* has less impact on the geometric mean of LM IC₅₀ as compared to that of the mutant *pfmdr*. Similarly, both LM and MQ are

unlike CQ in that they are rather more affected by *pfmdr-1* than by *pfcr*t mutation. Consequently, LM requires the mutant form of *pfmdr-1* to enhance its access into the DV where it is thought to produce its action [95, 96].

5.5. Effect on Dihydroartemisinin (DHA). It was found that DHA susceptibility was higher for strains harboring the wild rather than the mutant genotype of *pfmdr-1*. Meanwhile, its susceptibility was enhanced in the presence of the mutant genotype of *pfcr*t. This urged for DHA use to treat CQ resistant strains of *Plasmodium falciparum* [95]. According to a cross-genetic study run by Andriantsoanirina et al. 2009, in which transfecting of different CQ sensitive strains with *pfcr*t^{7G8} allele enhanced DHA susceptibility [97]. This mutation is not stable as it can be affected by drugs selection pressure. For instance, evolution of H209 from 7G8 strain which possessed C350R mutation due to the selection pressure of QN. The mutation reverted the strain into ART resistant strain as well.

5.6. Effect on Quinine Sensitivity. Both quinine (QN) and quinidine (QD) are famous antimalaria compounds that belong to quinoline family. It is thought that their target site of action is inside the DV. Their sensitivity is highly related to K76T mutation of *pfcr*t. For instance, 106/I strains, a CQ sensitive strain present in Sudan and is characterized by absence of *pfcr*t^{K76T}, are insensitive to both QN and QD [62].

Long term selection pressure of CQ on 106/I had induced either K76I or K76N mutation in *pfcr*t. Ubiquity of K76I turned the parasite into CQ resistant and produced a unique stereospecific response as it was turned into highly QN sensitive (17-folds decrease in IC₅₀) and QD insensitive (2-folds increase in IC₅₀) parasites. Interestingly, VPL reduced QN sensitivity and raised QD sensitivity in the mutated parasite. 106/I can expel QN outside the DV but this aptitude is lost once K76I is introduced. On the other hand, introduction of K76I mutation into 106/I had increased its *pfcr*t potency to expel QD extracellularly. This augments the direct interaction of these drugs with *pfcr*t [87].

Griffin et al. had investigated the impact of *pfcr*t mutations on antimalaria effect of cinchona alkaloids (C.A). C.A contain quinoline amino alcohols exemplified by quinine, hydroquinone, cinchonine, epiquinine, quinidine, hydroquinidine, cinchonidine, and epiquinidine [98]. Each of them contains two chiral centers located at positions 8 and 9. The first four species belong to erythroisomers while the next four are dextrorotatory isomers. Both dextrorotatory isomers were more potent toward CQ sensitive strains rather than the erythroisomers. Consequently, it was concluded that *pfcr*t is the major determinant of this stereospecific action. Furthermore, lysine ubiquity at position 76 in the wild form of *pfcr*t may prevent exodus of only dextrorotatory isomers through steric repulsion. The ionic group in the dextrorotatory isomers can face the 76 lysine in the wild form of *pfcr*t resulting in creation of a steric hindrance that hinders their exodus. On the other hand, erythroisomers dodge this steric hindrance as they face the 76 lysine residue of *pfcr*t through their hydrophobic part. As an exception, epiquinine and epiquinidine failed

to show any effect against *Plasmodium falciparum* as they lose the aptitude to inhibit β hematin formation. Exodus of cinchona alkaloids is inversely proportional to the positivity of *pfcr*t channel. On the other hand, anti-*Plasmodium* effect of the erythroisomers was quite similar in both CQ sensitive and resistant strains of *Plasmodium falciparum* but the difference was for the dextrorotatory ones. This supports the determinant role of *pfcr*t in the stereospecific action of C.A. The possibility that *pfmdr* mutations affect this stereospecificity was excluded as there was no any correlation between these stereoisomers anti-*Plasmodium* activity and ubiquity of different *pfmdr-1* mutation. Furthermore, there was no effect of stereoisomerism on binding of any of the cinchona quinoline alkaloids with β hematin [98].

5.7. Effect on Amodiaquine (AQ). Amodiaquine is a 4-aminoquinoline antimalaria drug whose mechanism of action is similar to CQ. It is effective against the Asian and African CQ resistant strains of *Plasmodium falciparum* but is ineffective against the South American ones. The latter are moderate CQ resistant and highly resistant to AQ. It was recommended by WHO to be used as a part of artemisinin combination therapy (ACT) in Africa [99]. The precise effect of both *pfcr*t and *pfmdr* on AQ resistance is still unclear. It was found that the *pfcr*t allele of the African strains is more linked to AQ resistance rather than *pfmdr-1* as cross-genetic studies revealed that the degree of resistance was similar when different *pfmdr-1* alleles had been transfected as partners with the African *pfcr*t^{CQR} allele [35].

5.8. Effect on Piperaquine. Previously, it was dictated that PIP IC₅₀ is high in CQ resistant strains of *Plasmodium falciparum*. In a cross-genetic study, where *pfcr*t^{7G8} allele was introduced into different CQ susceptible strains, it was found that it confers for higher PIP resistance. As an exception, PIP sensitivity was high in G224, a CQ sensitive strain carrying the same *pfcr*t^{7G8}, and D10^{*pfcr*t7G8}, a CQ susceptible strain transfected with *pfcr*t^{7G8} allele and H209, which carries a mutant *pfcr*t^{7G8} allele with C350R mutation [54].

6. Conclusion

It is noteworthy to point out that the problem of drug resistance to antimalarials is quite horrendous due to continuous emergence of drug resistant strains. Both *pfmdr-1* and *pfcr*t determine susceptibility of *Plasmodium falciparum* to antimalarials as they control the amount of the drug that accumulates inside the digestive vacuole. Efficacy of the drugs whose target site of action is intravacuolar increases if the abovementioned transporters shuffle them into the digestive vacuole and vice versa for those whose target site is extracellular. There is a close positive association between responses of *Plasmodium falciparum* to MQ, HF, LM, and DHA. These responses are inversely proportional to those of CQ. These changes are conferred by ubiquity of both *pfcr*t and *pfmdr-1* mutations. This observation suggests the presence of a common element of multigenic mechanism.

Studying the correlation between drug resistance in the parasites and genetic polymorphism may allow for developing new tools to predict responses to drugs.

Conflict of Interests

All authors declare that there is no conflict of interests regarding publication of this paper.

References

- [1] M. F. Boni, D. L. Smith, and R. Laxminarayan, "Benefits of using multiple first-line therapies against malaria," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 37, pp. 14216–14221, 2008.
- [2] J. N. Burrows, D. Leroy, J. Lotharius, and D. Waterson, "Challenges in antimalarial drug discovery," *Future Medicinal Chemistry*, vol. 3, no. 11, pp. 1401–1412, 2011.
- [3] J. C. Wootton, X. Feng, M. T. Ferdig et al., "Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*," *Nature*, vol. 418, no. 6895, pp. 320–323, 2002.
- [4] C. W. Chan, R. Spathis, D. M. Reiff, S. E. McGrath, R. M. Garruto, and J. K. Lum, "Diversity of *Plasmodium falciparum* chloroquine resistance transporter (pfcr) exon 2 haplotypes in the pacific from 1959 to 1979," *PLoS ONE*, vol. 7, no. 1, Article ID e30213, 2012.
- [5] S. V. Looareesuwan, C. Webster, H. K. Kyle et al., "Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand," *The American Journal of Tropical Medicine and Hygiene*, vol. 54, no. 1, pp. 62–66, 1996.
- [6] X. C. Ding, D. Ubben, and T. N. Wells, "A framework for assessing the risk of resistance for anti-malarials in development," *Malaria Journal*, vol. 11, article 292, 2012.
- [7] T. J. C. Anderson, S. Nair, H. Qin et al., "Are transporter genes other than the chloroquine resistance locus (pfcr) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance?" *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 6, pp. 2180–2188, 2005.
- [8] M. Korsinczyk, N. Chen, B. Kotecka, A. Saul, K. Rieckmann, and Q. Cheng, "Mutations in *Plasmodium falciparum* cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site," *Antimicrobial Agents and Chemotherapy*, vol. 44, no. 8, pp. 2100–2108, 2000.
- [9] J. M. Peters, N. Chen, M. Gatton et al., "Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in *Plasmodium falciparum*," *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 8, pp. 2435–2441, 2002.
- [10] P. Garner and P. M. Graves, "The benefits of artemisinin combination therapy for malaria extend beyond the individual patient," *PLoS Medicine*, vol. 2, article e105, 2005.
- [11] G. D. Shanks, "Treatment of falciparum malaria in the age of drug resistance," *Journal of Postgraduate Medicine*, vol. 52, no. 4, pp. 277–280, 2006.
- [12] G. Santos and N. V. Torres, "New targets for drug discovery against Malaria," *PLoS ONE*, vol. 8, no. 3, Article ID e59968, 2013.
- [13] M. T. Tse, "Antimalarial drugs: a treasure trove of potential antimalarials," *Nature Reviews Drug Discovery*, vol. 9, no. 7, pp. 516–517, 2010.
- [14] D. M. Molina, R. Jafari, M. Ignatushchenko et al., "Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay," *Science*, vol. 341, no. 6141, pp. 84–87, 2013.
- [15] P. D. Dobson, K. Lanthaler, S. G. Oliver, and D. B. Kell, "Implications of the dominant role of transporters in drug uptake by cells," *Current Topics in Medicinal Chemistry*, vol. 9, no. 2, pp. 163–181, 2009.
- [16] A. D. Djimdé, O. K. Doumbo, J. F. Cortese et al., "A molecular marker for chloroquine-resistant falciparum malaria," *The New England Journal of Medicine*, vol. 344, no. 4, pp. 257–263, 2001.
- [17] K. L. Waller, R. A. Muhle, L. M. Ursos et al., "Chloroquine resistance modulated in vitro by expression levels of the *Plasmodium falciparum* chloroquine resistance transporter," *Journal of Biological Chemistry*, vol. 278, no. 35, pp. 33593–33601, 2003.
- [18] W. M. Atroosh, H. M. Al-Mekhlafi, M. A. K. Mahdy, and J. Surin, "The detection of pfcr and pfmdr1 point mutations as molecular markers of chloroquine drug resistance, Pahang, Malaysia," *Malaria Journal*, vol. 11, article 251, 2012.
- [19] G. Dorsey, M. R. Kamya, A. Singh, and P. J. Rosenthal, "Polymorphisms in the *Plasmodium falciparum* pfcr and pfmdr1 genes and clinical response to chloroquine in Kampala, Uganda," *Journal of Infectious Diseases*, vol. 183, no. 9, pp. 1417–1420, 2001.
- [20] M. T. Duraisingh and A. F. Cowman, "Contribution of the pfmdr1 gene to antimalarial drug-resistance," *Acta Tropica*, vol. 94, no. 3, pp. 181–190, 2005.
- [21] R. N. Price, A.-C. Uhlemann, A. Brockman et al., "Mefloquine resistance in *Plasmodium falciparum* and increased pfmdr1 gene copy number," *The Lancet*, vol. 364, no. 9432, pp. 438–447, 2004.
- [22] K. Rungsihirunrat, W. Chaijareonkul, A. Seugorn, K. Na-Bangchang, and S. Thaitong, "Association between chloroquine resistance phenotypes and point mutations in pfcr and pfmdr1 in *Plasmodium falciparum* isolates from Thailand," *Acta Tropica*, vol. 109, no. 1, pp. 37–40, 2009.
- [23] V. Andriantsoanirina, A. Ratsimbaoa, C. Bouchier et al., "Chloroquine clinical failures in *P. falciparum* malaria are associated with mutant Pfmdr-1, not Pfcr in Madagascar," *PLoS ONE*, vol. 5, no. 10, Article ID e13281, 2010.
- [24] A. Van Helvoort, A. J. Smith, H. Sprong et al., "MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine," *Cell*, vol. 87, no. 3, pp. 507–517, 1996.
- [25] C. P. Sanchez, A. Rotmann, W. D. Stein, and M. Lanzer, "Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in *Plasmodium falciparum*," *Molecular Microbiology*, vol. 70, no. 4, pp. 786–798, 2008.
- [26] P. Rohrbach, C. P. Sanchez, K. Hayton et al., "Genetic linkage of pfmdr1 with food vacuolar solute import in *Plasmodium falciparum*," *The EMBO Journal*, vol. 25, no. 13, pp. 3000–3011, 2006.
- [27] L. von Seidlein, M. T. Duraisingh, C. J. Drakeley, R. Bailey, B. M. Greenwood, and M. Pinder, "Polymorphism of the Pfmdr1 gene and chloroquine resistance in *Plasmodium falciparum* in The Gambia," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 91, no. 4, pp. 450–453, 1997.
- [28] C. M. Wilson, A. E. Serrano, A. Wasley, M. P. Bogenschutz, A. H. Shankar, and D. F. Wirth, "Amplification of a gene related to mammalian mdr genes in drug-resistant *Plasmodium falciparum*," *Science*, vol. 244, no. 4909, pp. 1184–1186, 1989.
- [29] D. K. Raj, J. Mu, H. Jiang et al., "Disruption of a *Plasmodium falciparum* multidrug resistance-associated protein (PfMRP)

- alters its fitness and transport of antimalarial drugs and glutathione,” *Journal of Biological Chemistry*, vol. 284, no. 12, pp. 7687–7696, 2009.
- [30] E. Rosenberg, I. Litus, N. Schwarzfuchs et al., “pfmdr2 confers heavy metal resistance to *Plasmodium falciparum*,” *Journal of Biological Chemistry*, vol. 281, no. 37, pp. 27039–27045, 2006.
- [31] J. P. Rubio and A. F. Cowman, “*Plasmodium falciparum*: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite,” *Experimental Parasitology*, vol. 79, no. 2, pp. 137–147, 1994.
- [32] S. Briolant, M. Henry, C. Oeuvray et al., “Absence of association between piperazine *in vitro* responses and polymorphisms in the *pfcr1*, *pfmdr1*, *pfmrp*, and *pfmhe* genes in *Plasmodium falciparum*,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 9, pp. 3537–3544, 2010.
- [33] M. M. Póvoa, I. S. Adagu, S. G. Oliveira, R. L. D. Machado, M. A. Miles, and D. C. Warhurst, “Pfmdr1 (Asn)1042(ASp) and (Asp)1246(Tyr) polymorphisms, thought to be associated with chloroquine resistance, are present in chloroquine-resistant and -sensitive Brazilian field isolates of *Plasmodium falciparum*,” *Experimental Parasitology*, vol. 88, no. 1, pp. 64–68, 1998.
- [34] M. T. Duraisingh, C. J. Drakeley, O. Muller et al., “Evidence for selection for the tyrosine-86 allele of the pfmdr1 gene of *Plasmodium falciparum* by chloroquine and amodiaquine,” *Parasitology*, vol. 114, no. 3, pp. 205–211, 1997.
- [35] H. Tinto, L. Guekoun, I. Zongo, R. T. Guiguemdé, U. D’Alessandro, and J. B. Ouédraogo, “Chloroquine-resistance molecular markers (Pfcr1 T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso,” *Tropical Medicine and International Health*, vol. 13, no. 2, pp. 238–240, 2008.
- [36] G. C. Barrett, *Chemistry and Biochemistry of the Amino Acids*, Springer, Amsterdam, The Netherlands, 1985.
- [37] P. G. Bray, S. R. Hawley, M. Mungthin, and S. A. Ward, “Physicochemical properties correlated with drug resistance and the reversal of drug resistance in *Plasmodium falciparum*,” *Molecular Pharmacology*, vol. 50, no. 6, pp. 1559–1566, 1996.
- [38] H. A. Babiker, S. J. Pringle, A. Abdel-Muhsin, M. Mackinnon, P. Hunt, and D. Walliker, “High-level chloroquine resistance in Sudanese isolates of *Plasmodium falciparum* is associated with mutations in the chloroquine resistance transporter gene *pfcr1* and the multidrug resistance gene *pfmdr1*,” *Journal of Infectious Diseases*, vol. 183, no. 10, pp. 1535–1538, 2001.
- [39] K. Haruki, P. G. Bray, S. A. Ward, M. Hommel, and G. Y. Ritchie, “Chloroquine resistance of *Plasmodium falciparum*: further evidence for a lack of association with mutations of the pfmdr1 gene,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 88, no. 6, p. 694, 1994.
- [40] T. E. Wellem, L. J. Panton, I. Y. Gluzman et al., “Chloroquine resistance not linked to mdr-like genes in *Plasmodium falciparum* cross,” *Nature*, vol. 345, no. 6272, pp. 253–255, 1990.
- [41] L. K. Basco, J. L. Bras, Z. Rhoades, and C. M. Wilson, “Analysis of *pfmdr1* and drug susceptibility in fresh isolates of *Plasmodium falciparum* from Sub-Saharan Africa,” *Molecular and Biochemical Parasitology*, vol. 74, no. 2, pp. 157–166, 1995.
- [42] S. J. Foote, D. E. Kyle, R. K. Martin et al., “Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in *Plasmodium falciparum*,” *Nature*, vol. 345, no. 6272, pp. 255–258, 1990.
- [43] L. K. Basco and P. Ringwald, “Molecular epidemiology of malaria in Yaounde, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr 1) gene of *Plasmodium falciparum*,” *The American Journal of Tropical Medicine and Hygiene*, vol. 59, no. 4, pp. 577–581, 1998.
- [44] K. R. G. McCutcheon, J. A. Freese, J. A. Frean, B. L. Sharp, and M. B. Markus, “Two mutations in the multidrug-resistance gene homologue of *Plasmodium falciparum*, pfmdr1, are not useful predictors of in-vivo or in-vitro chloroquine resistance in southern Africa,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 93, no. 3, pp. 300–302, 1999.
- [45] M. Mungthin, S. Intanikom, N. Suwandittakul et al., “Distribution of *pfmdr1* polymorphisms in *Plasmodium falciparum* isolated from Southern Thailand,” *Malaria Journal*, vol. 13, no. 1, article 117, 2014.
- [46] M. B. Reed, K. J. Saliba, S. R. Caruana, K. Kirk, and A. F. Cowman, “Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*,” *Nature*, vol. 403, no. 6772, pp. 906–909, 2000.
- [47] C. E. Griffin, J. M. Hoke, U. Samarakoon et al., “Mutation in the *Plasmodium falciparum* CRT protein determines the stereospecific activity of antimalarial Cinchona alkaloids,” *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 10, pp. 5356–5364, 2012.
- [48] M. B. Reed, K. J. Saliba, S. R. Caruana, K. Kirk, and A. F. Cowman, “Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*,” *Nature*, vol. 403, no. 6772, pp. 906–909, 2000.
- [49] G. Y. Ritchie, M. Mungthin, J. E. Green, P. G. Bray, S. R. Hawley, and S. A. Ward, “In vitro selection of halofantrine resistance in *Plasmodium falciparum* is not associated with increased expression of Pgh1,” *Molecular and Biochemical Parasitology*, vol. 83, no. 1, pp. 35–46, 1996.
- [50] M. Chavchich, L. Gerena, J. Peters, N. Chen, Q. Cheng, and D. E. Kyle, “Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in *Plasmodium falciparum*,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 6, pp. 2455–2464, 2010.
- [51] J. Mu, M. T. Ferdig, X. Feng et al., “Multiple transporters associated with malaria parasite responses to chloroquine and quinine,” *Molecular Microbiology*, vol. 49, no. 4, pp. 977–989, 2003.
- [52] H. Zhang, E. M. Howard, and P. D. Roepe, “Analysis of the antimalarial drug resistance protein Pfcr1 expressed in yeast,” *Journal of Biological Chemistry*, vol. 277, no. 51, pp. 49767–49775, 2002.
- [53] A. B. Singh Sidhu, D. Verdier-Pinard, and D. A. Fidock, “Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by *pfcr1* mutations,” *Science*, vol. 298, no. 5591, pp. 210–213, 2002.
- [54] S. G. Valderramos, J. C. Valderramos, L. Musset et al., “Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in *Plasmodium falciparum*,” *PLoS pathogens*, vol. 6, no. 5, Article ID e1000887, 2010.
- [55] G. Awasthi and A. Das, “Genetics of chloroquine-resistant malaria: a haplotypic view,” *Memórias do Instituto Oswaldo Cruz*, vol. 108, no. 8, pp. 947–961, 2013.
- [56] V. S. M. A. D. Kolippakkam, “Amino acid physicochemical properties database,” *Bioinformatics*, vol. 1, no. 1, pp. 2–4, 2005.
- [57] J. Antosiewicz, J. A. McCammon, and M. K. Gilson, “Prediction of pH-dependent properties of proteins,” *Journal of Molecular Biology*, vol. 238, no. 3, pp. 415–436, 1994.

- [58] N. Chen, D. E. Kyle, C. Pasay et al., "Pfcrt allelic types with two novel amino acid mutations in chloroquine-resistant *Plasmodium falciparum* isolates from the Philippines," *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 11, pp. 3500–3505, 2003.
- [59] V. Lakshmanan, P. G. Bray, D. Verdier-Pinard et al., "A critical role for PfCRT K76T in *Plasmodium falciparum* verapamil-reversible chloroquine resistance," *EMBO Journal*, vol. 24, no. 13, pp. 2294–2305, 2005.
- [60] R. A. H. Umar, S. W. Hassan, M. J. Ladan, M. Nma Jiya, M. K. Abubakar, and U. Nata'ala, "The association of K76T mutation in Pfcrt gene and chloroquine treatment failure in uncomplicated *Plasmodium falciparum* malaria in a cohort of Nigerian children," *Journal of Applied Sciences*, vol. 7, no. 23, pp. 3696–3704, 2007.
- [61] S. G. Evans and I. Havlik, "In vitro drug interaction between amantadine and classical antimalarial drugs in *Plasmodium falciparum* infections," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 88, no. 6, pp. 683–686, 1994.
- [62] R. A. Cooper, M. T. Ferdig, X.-Z. Su et al., "Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in *Plasmodium falciparum*," *Molecular Pharmacology*, vol. 61, no. 1, pp. 35–42, 2002.
- [63] R. A. Bayoumi, H. A. Babiker, S. M. Ibrahim et al., "Chloroquine-resistant *Plasmodium falciparum* in Eastern Sudan," *Acta Tropica*, vol. 46, no. 3, pp. 157–165, 1989.
- [64] M. A. Travassos and M. K. Laufer, "Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations," *Pediatric Research*, vol. 65, no. 5, article 2, pp. 64R–70R, 2009.
- [65] J. Keen, G. A. Farcas, K. Zhong, S. Yohanna, M. W. Dunne, and K. C. Kain, "Real-time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant *Plasmodium falciparum* isolates from India," *Journal of Clinical Microbiology*, vol. 45, no. 9, pp. 2889–2893, 2007.
- [66] G. Awasthi, G. B. K. Satya, and A. Das, "Pfcrt haplotypes and the evolutionary history of chloroquine-resistant *Plasmodium falciparum*," *Memórias do Instituto Oswaldo Cruz*, vol. 107, no. 1, pp. 129–134, 2012.
- [67] R. K. Mehlotra, H. Fujioka, P. D. Roepe et al., "Evolution of a unique *Plasmodium falciparum* chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 22, pp. 12689–12694, 2001.
- [68] S. G. Valderramos and D. A. Fidock, "Transporters involved in resistance to antimalarial drugs," *Trends in Pharmacological Sciences*, vol. 27, no. 11, pp. 594–601, 2006.
- [69] P. P. Vieira, M. U. Ferreira, M. D. G. Alecrim et al., "pfcrt polymorphism and the spread of chloroquine resistance in *Plasmodium falciparum* populations across the Amazon Basin," *Journal of Infectious Diseases*, vol. 190, no. 2, pp. 417–424, 2004.
- [70] T. N. Bennett, A. D. Kosar, L. M. B. Ursos et al., "Drug resistance-associated pfCRT mutations confer decreased *Plasmodium falciparum* digestive vacuolar pH," *Molecular and Biochemical Parasitology*, vol. 133, no. 1, pp. 99–114, 2004.
- [71] A. B. S. Sidhu, D. Verdier-Pinard, and D. A. Fidock, "Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by pfcrt mutations," *Science*, vol. 298, no. 5591, pp. 210–213, 2002.
- [72] H. Jiang, N. Li, V. Gopalan et al., "High recombination rates and hotspots in a *Plasmodium falciparum* genetic cross," *Genome Biology*, vol. 12, no. 4, article R33, 2011.
- [73] T. Mita, A. Kaneko, F. Hombhanje et al., "Role of pfmdr1 mutations on chloroquine resistance in *Plasmodium falciparum* isolates with pfcrt K76T from Papua New Guinea," *Acta Tropica*, vol. 98, no. 2, pp. 137–144, 2006.
- [74] J. Papakrivovs, J. M. Sá, and T. E. Wellems, "Functional characterization of the *Plasmodium falciparum* chloroquine-resistance transporter (PfCRT) in transformed *Dictyostelium discoideum* vesicles," *PLoS ONE*, vol. 7, no. 6, Article ID e39569, 2012.
- [75] K. J. Saliba and K. Kirki, "pH regulation in the intracellular malaria parasite, *Plasmodium falciparum*. H⁺ extrusion via a V-type H⁺-ATPase," *The Journal of Biological Chemistry*, vol. 274, no. 47, pp. 33213–33219, 1999.
- [76] K. J. Saliba, R. J. W. Allen, S. Zissis, P. G. Bray, S. A. Ward, and K. Kirk, "Acidification of the malaria parasite's digestive vacuole by a H⁺-ATPase and a H⁺-pyrophosphatase," *Journal of Biological Chemistry*, vol. 278, no. 8, pp. 5605–5612, 2003.
- [77] A. M. Lehane and K. Kirk, "Chloroquine resistance-conferring mutations in pfcrt give rise to a chloroquine-associated H⁺ leak from the malaria parasite's digestive vacuole," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 12, pp. 4374–4380, 2008.
- [78] A. M. Lehane, R. Hayward, K. J. Saliba, and K. Kirk, "A verapamil-sensitive chloroquine-associated H⁺ leak from the digestive vacuole in chloroquine-resistant malaria parasites," *Journal of Cell Science*, vol. 121, no. 10, pp. 1624–1632, 2008.
- [79] M. Henry, S. Alibert, E. Orlandi-Pradines et al., "Chloroquine resistance reversal agents as promising antimalarial drugs," *Current Drug Targets*, vol. 7, no. 8, pp. 935–948, 2006.
- [80] D. C. Warhurst, "Polymorphism in the *Plasmodium falciparum* chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine," *Malaria Journal*, vol. 2, article 31, 2003.
- [81] O. K. Amodu, D. L. Hartl, and S. W. Roy, "Patterns of polymorphism in genomic regions flanking three highly polymorphic surface antigens in *Plasmodium falciparum*," *Molecular and Biochemical Parasitology*, vol. 159, no. 1, pp. 1–6, 2008.
- [82] S. G. Evans and I. Havlik, "*Plasmodium falciparum*: effects of amantadine, an antiviral, on chloroquine-resistant and -sensitive parasites in vitro and its influence on chloroquine activity," *Biochemical Pharmacology*, vol. 45, no. 5, pp. 1168–1170, 1993.
- [83] S. I. Hay, C. A. Guerra, A. J. Tatem, A. M. Noor, and R. W. Snow, "The global distribution and population at risk of malaria: past, present, and future," *Lancet Infectious Diseases*, vol. 4, no. 6, pp. 327–336, 2004.
- [84] M. L. Kelly, J. A. Cook, P. Brown-Augsburger, B. A. Heinz, M. C. Smith, and L. H. Pinto, "Demonstrating the intrinsic ion channel activity of virally encoded proteins," *FEBS Letters*, vol. 552, no. 1, pp. 61–67, 2003.
- [85] J. Le Bras and R. Durand, "The mechanisms of resistance to antimalarial drugs in *Plasmodium falciparum*," *Fundamental and Clinical Pharmacology*, vol. 17, no. 2, pp. 147–153, 2003.
- [86] P. G. Bray and S. A. Ward, "A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in *Plasmodium falciparum*," *Pharmacology and Therapeutics*, vol. 77, no. 1, pp. 1–28, 1998.
- [87] D. J. Johnson, D. A. Fidock, M. Mungthin et al., "Evidence for a central role for PfCRT in conferring *Plasmodium falciparum* resistance to diverse antimalarial agents," *Molecular Cell*, vol. 15, no. 6, pp. 867–877, 2004.

- [88] J. Wooden, E. E. Gould, A. T. Paull, and C. H. Sibley, "Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains," *Experimental Parasitology*, vol. 75, no. 2, pp. 207–212, 1992.
- [89] P. G. Bray, O. Janneh, K. J. Raynes, M. Mungthin, H. Ginsburg, and S. A. Ward, "Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum," *Journal of Cell Biology*, vol. 145, no. 2, pp. 363–376, 2000.
- [90] S. A. Peel, S. C. Merritt, J. Handy, and R. S. Baric, "Derivation of highly mefloquine-resistant lines from Plasmodium falciparum in vitro," *American Journal of Tropical Medicine and Hygiene*, vol. 48, no. 3, pp. 385–397, 1993.
- [91] S. A. Peel, P. Bright, B. Yount, J. Handy, and R. S. Baric, "A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro," *The American Journal of Tropical Medicine and Hygiene*, vol. 51, no. 5, pp. 648–658, 1994.
- [92] P. Lim, S. Chy, F. Ariey et al., "pfcr1 polymorphism and chloroquine resistance in Plasmodium falciparum strains isolated in Cambodia," *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 1, pp. 87–94, 2003.
- [93] G. Lefèvre, S. Looareesuwan, S. Treeprasertsuk et al., "A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand," *The American Journal of Tropical Medicine and Hygiene*, vol. 64, no. 5, pp. 247–256, 2001.
- [94] M. Nateghpour, S. A. Ward, and R. E. Howells, "Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum," *Antimicrobial Agents and Chemotherapy*, vol. 37, no. 11, pp. 2337–2343, 1993.
- [95] L. Mwai, S. M. Kiara, A. Abdirahman et al., "In vitro activities of piperazine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcr1 and pfmdr1," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 12, pp. 5069–5073, 2009.
- [96] L. Mwai, A. Diriye, V. Masseno et al., "Genome wide adaptations of Plasmodium falciparum in response to Lumefantrine selective drug pressure," *PLoS ONE*, vol. 7, no. 2, Article ID e31623, 2012.
- [97] V. Andriantsoanirina, A. Ratsimbaoa, C. Bouchier et al., "Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 11, pp. 4588–4597, 2009.
- [98] C. E. Griffin, J. M. Hoke, U. Samarakoon et al., "Mutation in the Plasmodium falciparum CRT protein determines the stereospecific activity of antimalarial Cinchona alkaloids," *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 10, pp. 5356–5364, 2012.
- [99] J. M. Sá, O. Twu, K. Hayton et al., "Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 45, pp. 18883–18889, 2009.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

